Transcatheter Aortic Valve Replacement
Conditions
Keywords
aortic stenosis, TAVI, Evolut R, Evolut Pro
Brief summary
Single arm, observational trial of Transcatheter Aortic Valve Implantation (TAVI) with the Medtronic Evolut R and Evolut Pro The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk.
Detailed description
The purpose of this study is to investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in septuagenarians with severe, symptomatic Aortic Stenosis (AS) and risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk. The primary objective of this trial is to evaluate device success of TAVI with the Evolut R and Evolut Pro systems in septuagenarians with risk factors for adverse surgical outcomes not captured by the traditional risk scores and therefore of intermediate surgical risk. The secondary objective is to assess early safety (at 30 days) and clinical efficacy (after 30 days) of the TAVI procedure. Exploratory objective: comparative health economics in septuagenarians with symptomatic severe aortic stenosis and intermediate surgical risk treated with Transcatheter Aortic Valve Implantation (TAVI) vs Surgical Aortic Valve Replacement (SAVR) (matched historic cohort)
Interventions
Transcatheter Aortic Valve Implantation with Evolut R or Evolut Pro
Sponsors
University of Athens
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 75-79 2. Subject must have Society of Thoracic Surgeons (STS) score \>=4% and \<=8% 3. Subject must have at least one from the risk factors presented below: i. Severely atherosclerotic or porcelain aorta ii. Internal Mammary Artery (IMA) or other conduit(s) crossing midline and/or adherent to posterior table of sternum iii. Pre-existing mechanical valve in any other position iv. Severe right ventricular dysfunction v. Hostile chest (abnormal chest wall anatomy due to severe kyphoscoliosis or other skeletal abnormalities, evidence of severe radiation damage, history of multiple recurrent pleural effusions causing internal adhesions) vi. Severe liver disease/cirrhosis vii. Frailty viii. Malignancy with life expectancy that exceeds 24 months ix. Renal replacement therapy with creatinine levels \>200mmol/L or 2.26 mg/dl 4. Heart team consisting of at least one interventional cardiologist and one cardiac surgeon agree on indication and treatment proposal, based on their clinical judgment (including anatomy assessment, risk factors, etc) 5. Critical aortic valve area defined as an initial aortic valve area of \<=1cm2 or aortic valve index \<0.6cm2/m2 6. In presence of normal left ventricular function: 1. Mean gradient \>40mmHg OR Vmax\>4m/sec OR 2. In presence of low flow, low gradient severe AS, a dobutamine stress echo must be conducted that demonstrates presence of contractile reserve defined as follows \>=20% increase in stroke volume and mean gradient \>40mmHg 7. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by New York Heart Association (NYHA) Functional Class II or greater 8. The subject is suitable for direct TAVI not preceded by balloon valvuloplasty according to the judgment of the treating physicians 9. The subject and the treating physician agree that the subject will return for all required post procedure follow-up visits.
Exclusion criteria
1. Hypersensitivity or contraindication to aspirin, heparin, clopidogrel, coumadin, nitinol, or sensitivity to contrast media which cannot be adequately pre-medicated; 2. Blood dyscrasias as defined: leukopenia (WBC\<1000/mm3), thrombocytopenia (platelet count \<50.000cells/mm3), history of bleeding diathesis or coagulopathy; 3. Ongoing sepsis, including active endocarditis 4. Any condition considered a contraindication to extracorporeal assistance; 5. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within six weeks prior treatment 6. Cardiogenic shock manifested by low cardiac output, vasopressor dependence or mechanical hemodynamic support; 7. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA) 8. Active gastrointestinal (GI) bleeding within the past 3 months 9. Subject refuses a blood transfusion; 10. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits); 11. Multivessel coronary artery disease with a Syntax score \>22 12. Estimated life expectancy of less than 24 months due to associated non-cardiac comorbid conditions 13. Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consentor adherence to the protocol required follow-up exams; 14. Currently participating in an investigational drug or another device trial (excluding registries) 15. Evidence of an acute myocardial infarction \<=30 days before the index procedure 16. Need for emergency surgery for any reason 17. Uncontrolled atrial fibrillation Anatomical
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Device success (VARC-2 criteria) | 30 days | 1. Absence of procedural mortality 2. Correct positioning of the prosthetic heart valve into the proper anatomical location 3. Intended performance of the prosthetic heart valve (mean aortic valve gradient\<20mmHg or peak velocity \< 3m/s, and no moderate or severe prosthetic valve regurgitation) as assessed with 24h post implantation and pre-discharge echocardiogram |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of All stroke (disabling and non-disabling) | 30 days | Early Safety |
| Rate of Life-threatening bleeding | 30 days | Early Safety |
| Rate of Acute Kidney Injury-Stage 2 or 3 (including renal replacement therapy) | 30 days | Early Safety |
| Rate of Coronary artery obstruction requiring intervention | 30 days | Early Safety |
| Rate of All-cause mortality | 30 days | Early Safety |
| Rate of Valve-related dysfunction requiring repeat procedure (BAV, TAVI or SAVR) | 30 days | Early Safety |
| Rate of New pacemaker implantation | 30 days | Early Safety |
| Rate of Hospitalizations for valve-related symptoms or worsening congestive heart failure NYHA class III or IV | after 30 days and up to 2 years | Clinical Efficacy |
| Rate of Valve related dysfunction | after 30 days and up to 2 years | Mean aortic valve gradient \>=20mmHg, Effective orifice area (EOA)\<=0.9-1.1cm2, and/or Dimensionless Valve Index (DVI)\<0.35 m/s and/or moderate or severe prosthetic valve regurgitation |
| Rate of Major vascular complication | 30 days | Early Safety |
Countries
Greece
Contacts
Primary ContactDimitris Tousoulis, Prof
Backup ContactKonstantinos Toutouzas, Prof
Outcome results
None listed